Epstein-Barr virus: novel patented therapeutics.

Expert Opin Ther Pat

Scientific Direction, Centro di Riferimento Oncologico, IRCCS, via Gallini, 2, 33081 Aviano, Italy.

Published: June 2010

Importance Of The Field: Therapeutic strategies against Epstein-Barr virus (EBV) infection and associated cancers are still limited. Due to the primary role of this virus in the pathogenesis of these diseases, molecules interfering with EBV protein functions may represent effective therapeutic tools to treat EBV-associated diseases.

Areas Covered In This Review: Active immunotherapeutic protocols targeting EBV and EBV-associated cancers are reviewed first; then, we reviewed adoptive cellular therapies, innovative pharmacological approaches and other non-conventional therapeutic molecules.

What The Reader Will Gain: The published literature, in particular patent publications on EBV therapeutic options, has been searched for relevant information. This information has been organized and discussed.

Take Home Message: Many promising therapeutic opportunities are identified. Among these, vaccination protocols and adoptive cellular therapies are the most advanced and reached Phase I/II clinical trials. Pharmacological approaches are at the moment limited to the laboratory phase.

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543771003796590DOI Listing

Publication Analysis

Top Keywords

epstein-barr virus
8
adoptive cellular
8
cellular therapies
8
pharmacological approaches
8
therapeutic
5
virus novel
4
novel patented
4
patented therapeutics
4
therapeutics field
4
field therapeutic
4

Similar Publications

Contribution of Blood Biomarkers to Multiple Sclerosis Diagnosis.

Neurol Neuroimmunol Neuroinflamm

March 2025

Servei de Neurologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.

Background And Objectives: Invasive procedures may delay the diagnostic process in multiple sclerosis (MS). We investigated the added value of serum neurofilament light chain (sNfL), glial fibrillary acidic protein (sGFAP), chitinase-3-like 1 (sCHI3L1), and the immune responses to the Epstein-Barr virus-encoded nuclear antigen 1 to current MS diagnostic criteria.

Methods: In this multicentric study, we selected patients from 2 prospective cohorts presenting a clinically isolated syndrome (CIS).

View Article and Find Full Text PDF

The Epstein-Barr virus (EBV) infects nearly 90% of adults globally and is linked to over 200,000 annual cancer cases. Immunocompromised individuals from conditions such as primary immune disorders, HIV, or posttransplant immunosuppressive therapies are particularly vulnerable because of EBV's transformative capability. EBV remodels B cell metabolism to support energy, biosynthetic precursors, and redox equivalents necessary for transformation.

View Article and Find Full Text PDF

Background: To develop an effective vaccine against Plasmodium vivax, the most widely dispersed human malaria parasite, it is critical to understand how coinfections with other pathogens could impact malaria-specific immune response. A recent conceptual study proposed that Epstein-Barr virus (EBV), a highly prevalent human herpesvirus that establishes lifelong persistent infection, may influence P. vivax antibody responses.

View Article and Find Full Text PDF

Epstein-Barr virus-associated smooth muscle tumors (EBV-SMTs) represent a rare category of soft tissue tumors that are predominantly seen in individuals with compromised immune systems. Pathologically, EBV-SMT has malignant potential because of its unpredictable nature. These tumors can manifest at various anatomical sites or even multiple lesions in different locations.

View Article and Find Full Text PDF

Introduction: Angioimmunoblastic T-cell lymphoma (AITL) is a rare and aggressive lymphoma with a poor prognosis. AITL is associated with Epstein-Barr virus (EBV)-positive B cells in most cases, suggesting a possible role for the virus in the pathobiology of AITL. Cell lines from AITL patients do not exist and models of human AITL are needed.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!